复星医药(600196.SH)：控股子公司药品芦沃美替尼片注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received acceptance from the National Medical Products Administration for the marketing application of Fumainin® (generic name: Luwomeitini tablets) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with Neurofibromatosis type 1 (NF1), and it has been included in the priority review process [1] Group 1 - The drug is an innovative small molecule chemical drug developed independently by the group [1] - Fumainin® acts as a selective inhibitor of MEK1/2 [1]